Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Cancer Gene Ther. 2011 Jan 14;18(5):326–335. doi: 10.1038/cgt.2010.82

Figure 4. Prevention of HER2/neu expressing tumor establishment.

Figure 4

Ad5 naïve (A) or Ad5 immune (B) BALB/c mice (n=7/group) were immunized with injection buffer (tumor controls), 1010 VP Ad5 [E1-, E2b-]-null (vector control) or 1010 VP Ad5 [E1-, E2b-]-HER2/neu (treatment) in the left flank on days −28, −21 and −14. On day 0 mice were inoculated with 106 CT26-HER2/neu cells subcutaneously in the left subcostal region. Tumor growth was monitored and volumes calculated. * Indicates days when Ad5 [E1-, E2b-]-HER2/neu treated mice had significantly smaller (p<0.01) tumors than both controls. Error bars represent the standard error of the means.